Windgap Medical

What Windgap Medical does

Windgap Medical is a Watertown, Massachusetts-based medical device company founded in 2011 that designs proprietary wet/dry dual-chamber autoinjector platforms for the delivery of complex injectable drugs. Its core technology uses a parallel dual-cartridge architecture with gas-powered actuation and a reciprocating mixing mechanism, enabling automatic reconstitution of lyophilized or powdered drugs, sequential delivery of combination therapies through a single needle, and handling of high-viscosity formulations (up to 5,000+ cP) and large volumes (up to 10 mL) without reformulation or cold-chain storage. The company markets five platforms: ANDIPen (compact 2-step rescue autoinjector for emergency epinephrine), DualFlo (sequential dual-drug delivery), OneMix (single-cycle reconstitution for lyophilized drugs), MultiMix (multi-cycle gas-powered mixing for complex biologics), and DuraMix (reusable platform for chronic/depot therapies); the LVDC platform extends the architecture to large-volume, high-viscosity applications.

Windgap operates as a B2B platform company, not selling devices directly to end users. Revenue is generated through feasibility studies, custom platform licensing, milestone-based development partnerships with pharmaceutical companies, and commercialization agreements with pharma partners that pay up-front, technical, and sales milestones plus royalties. The exclusive worldwide commercialization rights for the ANDIPen epinephrine autoinjector are held by ALK-Abelló. The company is trusted by five of the top ten biopharmaceutical companies, has collaborations with a top 5 global pharmaceutical company and Novo Nordisk, and is co-developing a cyanide antidote autoinjector with the University of Minnesota under NIH funding. Revenue is not commercially material yet and the company is private, having raised over $39 million in a 2022 Series B-1 led by Taiwania Capital.

Name

Windgap Medical

Legal name

Windgap Medical, Inc.

Website

https://windgapmedical.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Drug Delivery Devices / Autoinjector Platforms

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Auto-Injectors (Disposable & Reusable) (HLAHAIAB)

akta.pro secondary industry

Wearable Injectors & On-Body Delivery Systems (HLAHAIAE)

Keywords

• Autoinjector platforms
• Drug delivery devices
• Wet dry autoinjectors
• Biologic drug delivery
• Combination product devices

Headquarters

HQ city

Watertown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Product Licensing and Commercialization: Windgap licenses its technology platforms to pharmaceutical partners for commercialization. The ANDIpen platform is being commercialized by ALK-Abelló in exchange for up-front, technical, and sales milestone payments along with tiered royalties on net sales (USA) and profit sharing for international sales.
2. Feasibility Studies and Development Partnerships: Windgap conducts feasibility studies with pharmaceutical companies to demonstrate platform capabilities for their specific drug formulations. These partnerships can lead to full development collaborations and custom product programs.
3. Platform Technology Licensing: Windgap licenses its autoinjector platforms (DualFlo, OneMix, Multimix) to pharmaceutical partners for integration with their drug products, generating licensing fees and milestone payments during development.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Windgap Medical designs, develops, and licenses proprietary autoinjector platforms (ANDIPen, DualFlo, OneMix, Multimix, DuraMix, LVDC) that enable pharmaceutical partners to deliver complex injectable drugs—including lyophilized compounds, high-viscosity biologics, and combination therapies. The company operates a B2B partnership model, licensing its dual-chamber, gas-powered wet/dry drug delivery technology to biopharmaceutical firms for integration into their drug-device combination products.

Product overview

Windgap Medical is a multiplatform drug delivery company offering innovative autoinjector products that simplify, automate, and accelerate the administration of complex injectables. The portfolio includes four distinct platform products: ANDIPen® (compact rescue autoinjector for emergency epinephrine delivery with 2-step operation), DualFlo (sequential dual-drug delivery through a single needle), OneMix (single-cycle reconstitution for lyophilized drugs), and Multimix (multi-cycle gas-powered mixing for complex biologics and high-viscosity formulations). The platforms share a modular dual-cartridge architecture using standard ISO-compliant cartridges, enabling flexibility across different drug formulations including lyophilized drugs, biologics, suspensions, and combination therapies. The company also offers DuraMix as a reusable platform option for chronic therapies.

Differentiator

Problem solved

Functional benefit

Brands

• DualFlo: Sequential dual-drug delivery autoinjector platform for two liquid doses administered through a single needle
• OneMix
• MultiMix
• ANDIPen
• LVDC (Large Volume Dual Chamber)

Products and services

• ANDIPen® Compact 2-step dual-chamber rescue autoinjector for thermally stable subcutaneous/intramuscular drug delivery with automatic mixing and rapid dissolution of doses up to 0.3 mL. Designed to meet 99.999% reliability metrics for emergency applications and licensed to ALK-Abelló for worldwide commercialization.
• DualFlo Sequential dual-drug delivery autoinjector that administers two liquid doses in precise sequence through a single needle. Solves co-formulation challenges and enables combination therapy delivery with customizable timing between doses.
• OneMix 2-step autoinjector platform for highly soluble lyophilized drugs with single-cycle reconstitution and delivery. Designed for at-home or acute-use administration with gas-powered precision mixing; current advancement into next development phase with a leading pharmaceutical partner for combination drug products.
• Multimix Gas-powered autoinjector platform for complex drug formulations including biologics, suspensions, and lyophilized drugs. Features multi-cycle programmable mixing at any angle with viscosity support exceeding 5,000 cPs.
• DuraMix Reusable autoinjector platform designed for drug products requiring long-term administration. Built to reduce device waste while maintaining precision and reliability for chronic or depot therapy regimens.
• LVDC (Large Volume Dual Chamber) Autoinjector platform using side-by-side nested dual-cartridge architecture with proprietary mixing and delivery needle hub. Supports high-viscosity medications up to 5000+ cP and large volume injections up to 10 mL.
• Feasibility Studies and Custom Development Programs Feasibility study and custom development services offered to pharmaceutical partners to demonstrate autoinjector platform capabilities for specific drug formulations before committing to full development collaborations.

Quantifiable outcome

• 99% reduction in reconstitution time for lyophilized drugs in feasibility studies (from hours to seconds)
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core, minor and strategic.

• Leading Pharmaceutical Partner (OneMix)coreStrategic or Co-development Partner · 5 May 2025Advancement to next phase of development with a leading pharmaceutical partner using Windgap's OneMix platform, a single-use autoinjector designed for mixing and delivering combination drug products. The milestone reflects continued progress in translating Windgap's proprietary delivery technologies into viable commercial drug-device combinations.
• Top 5 Global Pharmaceutical CompanycoreStrategic or Co-development Partner · 20 April 2025Strategic multi-program collaboration with a top 5 global pharmaceutical company to advance drug-device combination products using Windgap's proprietary autoinjector platforms. The partnership encompasses multiple programs and underscores growing demand for Windgap's innovative delivery technologies in complex drug formulations.
• University of Minnesota Twin CitiescoreStrategic or Co-development Partner · 15 January 2020$3.2 million NIH CounterACT grant collaboration to develop a cyanide antidote autoinjector for first responders. Researchers from the University's Center for Drug Design and College of Pharmacy collaborate with Windgap to design an autoinjector for sulfanegen antidote delivery. The collaboration aims to develop a tool for saving victims of cyanide poisoning from building fires, industrial accidents, or terrorist attacks.
• ALK-AbellócoreChannel Partner/ Reseller/ Distributor · 9 August 2019Strategic partnership with ALK-Abelló A/S (Danish pharmaceutical company) for worldwide commercialization of Windgap's epinephrine autoinjector. ALK holds exclusive worldwide sales and distribution rights in exchange for up-front, technical, and sales milestone payments along with tiered royalties on net sales in the USA and profit sharing for products sold outside the USA. Windgap estimates the EAI market in the USA exceeds USD 1 billion annually.
• Allergy Partners, P.A.minorStrategic or Co-development PartnerWith over 175 providers in 20 states, Allergy Partners is the largest allergy, asthma, and immunology practice in the United States, listed as an investor and strategic partner.
• Novo NordiskstrategicStrategic or Co-development PartnerRecent collaboration highlighted in investor relations as part of Windgap's strategic partnerships with industry leaders that accelerate development processes and expand reach in the global healthcare market.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• SHL Medical: One of the world's largest independent manufacturers of autoinjectors and pen injectors serving the same pharmaceutical partner base. Directly comparable as a drug-delivery device OEM targeting the same lyophilized, biologic, and combination-therapy programs.
• Ypsomed: Swiss developer and manufacturer of injection and infusion systems including the YpsoMate 2-step autoinjector. Closely comparable platform approach for self-administered injectables targeting pharma partners.
• Phillips-Medisize (a Molex company): Contract developer of drug-delivery devices including autoinjectors and connected injectors for pharma. Notably linked to Molex Ventures (Koch), which is itself an investor in Windgap—making it a closely comparable combination-product device peer.
• Owen Mumford: UK-based specialist in autoinjectors, pen injectors, and capillary blood sampling devices for pharmaceutical and diagnostic partners. Closely comparable as a focused auto-injector OEM serving global pharma.
• Haselmeier (medmix): Developer of subcutaneous self-injection devices including autoinjectors for pharma combination products, now part of medmix. Direct peer for dual-chamber and self-administration autoinjector programs.

Broad incumbents

• West Pharmaceutical Services: Large established drug-delivery and containment device manufacturer (auto-injectors, prefilled syringe systems, elastomers) serving the same top-10 pharma customers with broader portfolio offerings. Direct overlap on combination-product device platforms.
• Becton, Dickinson and Company (BD): BD Pharmaceutical Systems supplies prefilled syringes, autoinjectors (BD Physioject), and combination-product services to the same global biopharma customer set. Competes in auto-injector manufacturing and integrated drug-delivery solutions.
• Stevanato Group: Provides drug containment, drug delivery (including auto-injectors and on-body devices), and integrated fill-finish services. Comparable as a broad-incumbent device+services platform serving large pharma.
• Kindeva Drug Delivery: CDMO combining drug formulation, fill-finish, and device (autoinjector, inhaler) capabilities carved out from 3M. Windgap's CEO Aaron Mann previously led Kindeva, making it a closely linked incumbent across drug-device combination products.

Emerging players

• Halozyme Therapeutics (Antares Pharma): Halozyme acquired Antares Pharma for its auto-injector and patch injector platform serving pharma partners. Comparable in targeting self-administered high-viscosity biologics and combination therapy delivery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/windgap-medical-inc-
• Xx.com/windgapmedical
• Facebookfacebook.com/WindgapMedical

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds13 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Windgap Medical